Design Therapeutics, Inc.
- DSGN
- NASDAQ
- Biotechnology
- Friedreich's Ataxia Treatments
- Nucleotide Repeat Expansion Therapeutics
$10.64
Today +3.20%Quote Oct 19, 2026, 08:00 PM UTC
−13.07%over the last month
Max drawdown −26.1%From 1-month high −19.1%3 months −11.8%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Design Therapeutics
Design Therapeutics, Inc. is a biopharmaceutical company in the preclinical phase that focuses on creating treatments for genetic conditions stemming from nucleotide repeat expansions. Its current pipeline targets Friedreich's Ataxia (FA), a severe, progressive, monogenic, and autosomal recessive disease.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
55
Market value
$665.9M
Quote Oct 19
Floor
$10.54
1.0% below price
Resistance
$11.59
9.0% above price
Price vs analyst targets
7 analysts
Lowest target
$20.00Highest target
$26.00
$20.00Highest target
$26.00
- Price $10.64
- Average target $22.33
- Analysts' target range
The price is below even the lowest analyst target. Analysts' average target sits about 110% higher.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about DSGNPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free